, Volume 26, Issue 9, pp 15-18

Tumour necrosis factor (TNF) inhibitors are an effective option in the management of Crohn’s disease

  • show all 0 hide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The aim of management of Crohn’s disease is to reduce the impact of the disease. However, symptom control is not sufficient to avoid the complications of Crohn’s disease, thus necessitating the introduction of stricter treatment goals, including mucosal healing. The optimal utilization of tumour necrosis factor inhibitors can affect the natural history of Crohn’s disease, induce mucosal healing and reduce hospitalization and the need for surgery.

Major clinical challenge …

Crohn’s disease, a chronic, heterogeneous disorder with an unpredictable, relapsing course, is characterized by mucosal inflammation of the gastrointestinal tract.[1] It may be defined by location (e.g. localized ileocaecal, colonic or extensive disease) or by course (e.g. newly diagnosed, early relapse, or steroid-refractory disease),[2] and comprises one of the two prevailing types of inflammatory bowel disease (IBD).[1]

The precise aetiology of Crohn’s disease is unknown and a causal therapy is not available.[1] Alth